Antibodies against alpha-synuclein: tools and therapies

Nishant N. Vaikath, Issam Hmila, Vijay Gupta, Daniel Erskine, Martin Ingelsson, Omar M.A. El-Agnaf*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

49 Citations (Scopus)

Abstract

Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α-synuclein (α-syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α-syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that alleviate the accumulation of intracellular aggregated α-syn and associated pathology in cellular and preclinical models of synucleinopathies. So far, antibodies have been the first choice as tools for research and diagnosis and currently, a wide variety of antibody fragments have been developed as an alternative to full-length antibodies for increasing its therapeutic usefulness. Recently, conformation specific antibody-based approaches have been found to be promising as therapeutic strategies, both to block α-syn aggregation and ameliorate the resultant cytotoxicity, and as diagnostic tools. In this review, we summarize different α-syn specific antibodies and provide their usefulness in tackling synucleinopathies. (Figure presented.). This article is part of the Special Issue “Synuclein”.

Original languageEnglish
Pages (from-to)612-625
Number of pages14
JournalJournal of Neurochemistry
Volume150
Issue number5
DOIs
Publication statusPublished - 2019

Keywords

  • antibodies
  • synucleinopathies
  • α-synuclein

Fingerprint

Dive into the research topics of 'Antibodies against alpha-synuclein: tools and therapies'. Together they form a unique fingerprint.

Cite this